JUNS
NASDAQ
US
Jupiter Neurosciences, Inc. - Common Stock
$0.37
▼ $-0.01
(-2.89%)
Vol 42K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$35.1M
Margin
-165.8%
D/E
255.02
Beta
0.33
52W
$1–$13
Wall Street Consensus
7 analysts · Apr 20262
Strong Buy
4
Buy
1
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 60.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.07 | $-0.07 | +$0.00 |
| Sep 2025 | $-0.08 | $-0.07 | +$0.01 |
| Jun 2025 | $-0.07 | $-0.07 | +$0.00 |
| Mar 2025 | $-0.03 | $-0.05 | $-0.02 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$591K | -$1.5M | -$1.5M | -$2.3M | -$2.3M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | — | — | — | — | — |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -165.8% | -165.8% | -165.8% | -165.8% | -165.8% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 10.93 | 4.78 | 10.93 | 10.93 | 255.02 | 255.02 |
| Current Ratio | 1.07 | 1.91 | 1.07 | 1.07 | 0.65 | 0.65 |
Key Ratios
ROA (TTM)
-155.1%
P/B
84.9
EPS (TTM)
$-0.18
52W High
$12.81
52W Low
$0.51
$0.51
52-Week Range
$12.81
Financial Health
Free Cash Flow
-$1.2M
Net Debt
-$543K
Cash
$724K
Total Debt
$180K
As of Sep 30, 2025
How does JUNS compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
JUNS valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(5.0)
vs Peers
vs Industry
Overvalued
P/B ratio
84.9
▲
3905%
above
peers
(2.1)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
JUNS profitability vs Pharmaceuticals peers
ROE
—
▼
0%
below
peers
(-54.3%)
vs Peers
vs Industry
Top tier
Net margin
-165.8%
▼
250%
below
peers
(-47.4%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(68.3%)
vs Peers
vs Industry
In line
ROA
-155.1%
▼
314%
below
peers
(-37.4%)
vs Peers
vs Industry
Weak
JUNS financial health vs Pharmaceuticals peers
D/E ratio
255.0
▲
16460%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
0.7
▼
81%
below
peers
(3.4)
vs Peers
vs Industry
Low liquidity
Beta
0.3
▼
65%
below
peers
(0.9)
vs Peers
vs Industry
More volatile
JUNS fundamentals radar
JUNS
Peer median
Industry
JUNS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
JUNS vs peers: key metrics
Latest News
No related news yet